Patents by Inventor Anthony E. Ting
Anthony E. Ting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181651Abstract: The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).Type: ApplicationFiled: April 23, 2021Publication date: June 15, 2023Applicant: ABT Holding CompanyInventors: Anthony E. Ting, Eric D. Jenkins, Alice Valentin-Torres
-
Publication number: 20230131225Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.Type: ApplicationFiled: September 29, 2022Publication date: April 27, 2023Inventors: Jason A. Hamilton, Anthony E. Ting, Robert W. Mayas
-
Patent number: 11071752Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.Type: GrantFiled: April 16, 2019Date of Patent: July 27, 2021Assignees: ABT Holding Company, Houston Methodist HospitalInventors: Saverio La Francesca, Anthony E. Ting, Robert J. Deans
-
Publication number: 20190269725Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.Type: ApplicationFiled: April 16, 2019Publication date: September 5, 2019Inventors: Saverio La Francesca, Anthony E. Ting, Robert J. Deans
-
Patent number: 10272109Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.Type: GrantFiled: January 8, 2018Date of Patent: April 30, 2019Assignee: ABT Holding CompanyInventors: Saverio La Francesca, Anthony E. Ting, Robert J. Deans
-
Publication number: 20190048314Abstract: The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.Type: ApplicationFiled: March 8, 2018Publication date: February 14, 2019Applicant: ABT Holding CompanyInventors: Juliana Megan Woda, Anthony E. Ting, Nicholas A. Lehman
-
Publication number: 20180325945Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.Type: ApplicationFiled: January 8, 2018Publication date: November 15, 2018Inventors: Saverio LaFrancesca, Anthony E. Ting, Robert J. Deans
-
Publication number: 20160282336Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.Type: ApplicationFiled: September 17, 2015Publication date: September 29, 2016Applicant: ABT Holding CompanyInventors: Jason A. Hamilton, Anthony E. Ting, Robert W. Mays
-
Publication number: 20140295442Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Applicant: ABT Holding CompanyInventors: Jason A. Hamilton, Anthony E. Ting, Robert W. Mays
-
Publication number: 20140242629Abstract: The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.Type: ApplicationFiled: February 25, 2014Publication date: August 28, 2014Applicant: ABT Holding CompanyInventors: Juliana Megan Woda, Anthony E. Ting, Nicholas A. Lehman
-
Publication number: 20110305638Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate macrophage activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate macrophage activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency to modulate macrophage activation.Type: ApplicationFiled: March 25, 2011Publication date: December 15, 2011Applicants: Case Western Reserve University, ABT Holding CompanyInventors: Anthony E. Ting, Robert W. Mays, Jason A. Hamilton, Sarah P. Busch, Jerry Silver
-
Publication number: 20110212069Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.Type: ApplicationFiled: March 25, 2011Publication date: September 1, 2011Applicant: ABT Holding CompanyInventors: Jason A. Hamilton, Anthony E. Ting, Robert W. Mays
-
Publication number: 20110206647Abstract: The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.Type: ApplicationFiled: March 25, 2011Publication date: August 25, 2011Applicant: ABT Holding CompanyInventors: Juliana Megan Woda, Anthony E. Ting, Nicholas A. Lehman